We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alignment Healthcare (ALHC) Soars 25.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Alignment Healthcare (ALHC - Free Report) shares rallied 25.1% in the last trading session to close at $19.2. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.6% loss over the past four weeks.
Alignment Healthcare scored a strong price increase, on investors’ optimism following the company’s latest presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in Florida. CEO John Kao highlighted the company’s medical management capabilities as a key differentiator and also noted plans to enter into a couple of large markets within existing states in 2027. Further, Alignment Healthcare has been recently named to the Fortune 1000 2026 list for the second consecutive year, reflecting its continued growth, strong financial performance and accelerating momentum in delivering senior-focused healthcare.
This Medicare Advantage insurer is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +85.7%. Revenues are expected to be $1.31 billion, up 29% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Alignment Healthcare, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ALHC going forward to see if this recent jump can turn into more strength down the road.
Alignment Healthcare is part of the Zacks Medical Services industry. Bausch + Lomb (BLCO - Free Report) , another stock in the same industry, closed the last trading session 3.1% higher at $15.65. BLCO has returned -5.3% in the past month.
For Bausch + Lomb, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.16. This represents a change of +128.6% from what the company reported a year ago. Bausch + Lomb currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Alignment Healthcare (ALHC) Soars 25.1%: Is Further Upside Left in the Stock?
Alignment Healthcare (ALHC - Free Report) shares rallied 25.1% in the last trading session to close at $19.2. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.6% loss over the past four weeks.
Alignment Healthcare scored a strong price increase, on investors’ optimism following the company’s latest presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in Florida. CEO John Kao highlighted the company’s medical management capabilities as a key differentiator and also noted plans to enter into a couple of large markets within existing states in 2027. Further, Alignment Healthcare has been recently named to the Fortune 1000 2026 list for the second consecutive year, reflecting its continued growth, strong financial performance and accelerating momentum in delivering senior-focused healthcare.
This Medicare Advantage insurer is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +85.7%. Revenues are expected to be $1.31 billion, up 29% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Alignment Healthcare, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ALHC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Alignment Healthcare is part of the Zacks Medical Services industry. Bausch + Lomb (BLCO - Free Report) , another stock in the same industry, closed the last trading session 3.1% higher at $15.65. BLCO has returned -5.3% in the past month.
For Bausch + Lomb, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.16. This represents a change of +128.6% from what the company reported a year ago. Bausch + Lomb currently has a Zacks Rank of #3 (Hold).